Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1
29 déc. 2016 04h04 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 29, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics...
Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer
21 déc. 2016 16h33 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data from the AIPAC Phase IIb clinical trial for...
Prima BioMed Receives UK Approval for AIPAC Study
19 déc. 2016 19h00 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 19, 2016) -
Competent Authority and Ethics Committee approval received in the United Kingdom for AIPAC
Recruitment...
Prima BioMed Announces ADR Ratio Change
18 déc. 2016 18h39 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 18, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces a ratio change for the Company's American Depositary Receipt ("ADR")...
Prima to Present at 2016 Society for Immunotherapy of Cancer Conference
12 oct. 2016 21h36 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Oct 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") announces that the submission titled "LAG-3Ig (IMP321) in combination with anti-PD-1 therapy"...
Prima Abstracts Accepted for Poster Presentation at ESMO Symposium on Immuno-Oncology
06 oct. 2016 01h54 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Oct 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces that an abstract for each of its two clinical trials for IMP321 has...
European Patent Grants for IMP731 Antibody
24 août 2016 20h34 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Aug 24, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3...
Prima BioMed Ltd: Operational Update
18 août 2016 05h00 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Aug 18, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), has provided an update on the Company's cash position and the recruitment progress in its two active...
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
10 août 2016 03h54 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Aug 10, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), has received notification from the Listing Qualifications Department of The...
Prima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors
12 juil. 2016 03h37 HE
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jul 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announced a new collaborative study investigating the intra-tumoural injection of IMP321. The...